Fibrinogen from human plasma
SIGMA/F4883 - 35-65% protein (≥90% of protein is clottable).
Synonym: Factor I
CAS Number: 9001-32-5
EC Number: 232-598-6
MDL Number: MFCD00131060
Product Type: Chemical
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: F4883-5G
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: F4883-500MG
| biological source | human plasma |
| concentration | 35-65% protein (biuret) |
| description | essentially plasmin(ogen) free |
| form | powder |
| mol wt | α-chain 63.5 kDa |
| β-chain 56 kDa | |
| γ chain 47 kDa (about 4% carbohydrate content) | |
| soluble dimer 340 kDa | |
| quality | 35-65% protein (≥90% of protein is clottable). |
| Quality Level | 300  |
| solubility | 0.9% NaCl: soluble |
| storage temp. | −20°C |
| technique(s) | cell culture | mammalian: suitable |
| UniProt accession no. | P02671  |
| P02675 |
|
| P02679 |
| Analysis Note: | Protein determined by biuret |
| Application: | Fibrinogen from human plasma has been used for- • fibrinogen adsorption assay performed on swCNTs (single-walled carbon nanotubes) • the characterization of fibrinogen structure in the presence of CNT using CD (Circular dichroism) spectroscopy and temperature scan • the preparation of RBC suspension obtained from venous blood of antecubital vein, to assess RBC aggregability • fibrinolysis assay performed on mouse embryonic fibroblasts (MEFs) • the preparation of fibrinogen-labeled gold (Fgn/Au) • the quantification of in vitro angiogenesis by human microvascular endothelial cells and • the assessment of fibrin-induced apoptosis and differentiation-regulatio |
| Biochem/physiol Actions: | Acute phase protein that is part of the coagulation cascade of proteins. |
| Biochem/physiol Actions: | Fibrinogen is an acute phase protein that is part of the coagulation cascade of proteins. The end result of the cascade is the production of thrombin that converts fibrinogen to fibrin. Thrombin rapidly proteolyses fibrinogen, releasing fibrinopeptide A. The loss of this small peptide is not sufficient to make the resulting fibrin molecule insoluble, but it tends to form complexes with adjacent fibrin and fibrinogen molecules. Thrombin then cleaves a second peptide, fibrinopeptide B, from fibrin and the fibrin monomers formed then polymerize spontaneously to form an insoluble gel. The polymerized fibrin is held together by noncovalent and electrostatic forces and stabilized by the transamidating enzyme, factor XIIIa, that is produced by the action of thrombin on factor XIII. The insoluble fibrin aggregates (clots) and aggregated platelets then block the damaged blood vessel and prevent further bleeding. The amount of fibrinogen in the plasma can serve as a nonspecific indicator of whether or not an inflammatory process is present in the body. Fibrinogen from any mammalian source will be cleaved by thrombin from any mammalian source. |
| Biochem/physiol Actions: | Fibrinogen is an acute-phase inflammatory protein, which plays an essential role in blood clotting. Coronary heart disease is linked to the plasma levels of fibrinogen in Chinese population, and might have potential as a marker and risk factor for the same. A -455 allele of fibrinogen β (FGB) chain is linked with poor survival in Caucasian women with Finnish stroke. Ischemic stroke preceded by hyperfibrinogenemia has poor outcome, which is independent of the baseline fibrinogen concentration. |
| Disclaimer: | RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization. |
| Features and Benefits: | Source material has tested negative for HIV and HBsAg. |
| General description: | Fibrinogen was the first blood coagulation factor to be identified, and it is a precursor of fibrin protein. This protein is composed of two chains, each of which is composed of three chains- α, β and γ. These three subunits are coded by three genes located in the human chromosomal locus 4q23-q32, and spans 51kb. |
| Packaging: | 1, 5 g in glass bottle |
| Packaging: | 500 mg in glass bottle |
| Physical form: | Lyophilized powder containing sodium citrate and sodium chloride. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 12352202 |